NCT06646458

Brief Summary

The purpose of this interventional, single-arm pilot study aimed to evaluate the new product that newly developed contains a mixture of prebiotics and probiotics to gain insights of GI function acceptance, microbiological composition and related benefits before and after study product consumption in population aged between 50-70 years. This project also serves the purpose of formulating conceptual hypothesis and directions of exploration for future research. The main questions it aims to answer are:

  1. 1.Microbiological change from stool samples collected at baseline and in the days after study product usage
  2. 2.Gastrointestinal function and acceptance assessed during the study period
  3. 3.Health related outcomes assessed via wearable device
  4. 4.Any safety events
  5. 5.Take study product
  6. 6.Visit the study site
  7. 7.Collect the stool sample
  8. 8.Record daily gastrointestinal tolerance and health data

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for not_applicable healthy-volunteers

Timeline
Completed

Started Feb 2025

Shorter than P25 for not_applicable healthy-volunteers

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 1, 2024

Completed
16 days until next milestone

First Posted

Study publicly available on registry

October 17, 2024

Completed
4 months until next milestone

Study Start

First participant enrolled

February 7, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 14, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 14, 2025

Completed
Last Updated

July 25, 2025

Status Verified

July 1, 2025

Enrollment Period

1 month

First QC Date

October 1, 2024

Last Update Submit

July 24, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Gastrointestinal (GI) function Questionnaire

    Gastrointestinal symptoms assessed the tolerance of product via the Incidence of gastrointestinal discomfort

    from baseline (0 day) to the end of treatment at 28 days

Secondary Outcomes (1)

  • Microbiological analysis

    from baseline to the end of study at 28 days

Other Outcomes (1)

  • Sleep quality analysis from wearable device

    from baseline (0 days) to end of treatment at 28 days

Study Arms (1)

Milk Powder (study product) usage group

EXPERIMENTAL

Investigational Product Participants in this arm will need to take 2 times every day from baseline visit to 28 days.

Other: Healthy Elderly Volunteers

Interventions

Take the elderly milk power 2 times every day up to 28 days

Milk Powder (study product) usage group

Eligibility Criteria

Age50 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 50-70 years (bounds included)
  • Body Mass Index (BMI) between 18.5 (bound included) and 30 (bound excluded) kg/m2.
  • Ability to comply with the protocol and assessment window:
  • Product intake according to instructions.
  • Willing to collect, store, deliver stool sample according to instructions.
  • Willing to adhere to instructions and restrictions during entire study period\*:
  • No probiotic supplementations or products supplemented with probiotics.
  • No dietary fiber supplements.
  • No medications may modify gastrointestinal function.
  • Fluency in speaking, reading and writing in mandarin.
  • Capability of the subject to install and use the secure study platform on the smartphone during entire study period.
  • Written informed consent. \*Overruled in case of medical needs.

You may not qualify if:

  • Known / Existing gastrointestinal diseases or disorders diagnosed by a physician that may interfere with study.
  • Known / Existing milk protein allergies, lactose intolerance or other allergies to product ingredients.
  • Known / Existing immune diseases or disorders diagnosed by a physician that may interfere with study.
  • Use of any medication may modify gastrointestinal function: tricyclic antidepressants, SSRIs/antidepressants, opioids, ACE inhibitor, bate sympathomimetics, systemic antibiotics, intestinal antiseptics, anti-inflammatory medicines (including nonsteroidal anti-inflammatory drugs \[NSAIDs\] and aspirin), anti-histamines, steroids, corticosteroids, laxatives, anti-diarrhoea medication, prokinetics/dopamine-antagonists, metformin, statins, or any other stomach medication (including proton pump inhibitor \[PPIs\], antiacids, and antihistamine2 blockers) within 8 weeks prior to enrolment.
  • Consumption of probiotic supplementations or products supplemented with probiotics within 4 weeks prior to enrolment.
  • Subject following a special diet, including but not limited to vegan diet, ketogenic diet, low fiber diet, thickening diet etc.
  • Incapability to comply with protocol as per the judgement of the investigator.
  • Participation in any other studies involving investigational or marketed products concomitantly or 2 weeks prior to enrolment.
  • Employees and/or children/family member or relatives of employees of Danone or the participating site.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lisheng Scientific Lab

Shanghai, Shanghai Municipality, China

Location

Study Officials

  • Charlie Zhang, MD

    Lisheng Scientific Lab

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 1, 2024

First Posted

October 17, 2024

Study Start

February 7, 2025

Primary Completion

March 14, 2025

Study Completion

March 14, 2025

Last Updated

July 25, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations